$10.25
3.94% yesterday
Nasdaq, Jun 13, 10:17 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$10.25
+0.06 0.59% 1M
-3.68 26.42% 6M
-2.97 22.47% YTD
-10.45 50.48% 1Y
-6.01 36.96% 5Y
-1.76 14.65% 10Y
-1.76 14.65% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.42 3.94%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $881.99m
Enterprise Value $710.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.26
P/S ratio (TTM) P/S ratio 20.17
P/B ratio (TTM) P/B ratio 4.10
Revenue (TTM) Revenue $43.72m
EBIT (operating result TTM) EBIT $-343.67m
Free Cash Flow (TTM) Free Cash Flow $-286.52m
Cash position $516.31m
EPS (TTM) EPS $-3.86
P/E forward negative
P/S forward 7.05
EV/Sales forward 5.68
Short interest 30.37%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
92%
Hold
8%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
44 44
-
100%
- Direct Costs 1.71 1.71
-
4%
26 26
-
59%
- Selling and Administrative Expenses 139 139
78% 78%
318%
- Research and Development Expense 247 247
33% 33%
564%
-344 -344
30% 30%
-786%
- Depreciation and Amortization 0.01 0.01
50% 50%
0%
EBIT (Operating Income) EBIT -344 -344
30% 30%
-786%
Net Profit -331 -331
38% 38%
-758%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
2 days ago
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –
Neutral
GlobeNewsWire
2 days ago
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Synda...
Neutral
GlobeNewsWire
9 days ago
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to purchase up to 119,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four yea...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 270
Founded 2005
Website syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today